CN1671375A - 施用罗替戈汀的改良透皮递药系统 - Google Patents

施用罗替戈汀的改良透皮递药系统 Download PDF

Info

Publication number
CN1671375A
CN1671375A CNA038184257A CN03818425A CN1671375A CN 1671375 A CN1671375 A CN 1671375A CN A038184257 A CNA038184257 A CN A038184257A CN 03818425 A CN03818425 A CN 03818425A CN 1671375 A CN1671375 A CN 1671375A
Authority
CN
China
Prior art keywords
rotigotine
tds
matrix
adhesive
self
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038184257A
Other languages
English (en)
Chinese (zh)
Inventor
M·汉奈
D·W·沙赫特
H·-M·沃尔夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
Schwarz Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schwarz Pharma AG filed Critical Schwarz Pharma AG
Publication of CN1671375A publication Critical patent/CN1671375A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA038184257A 2002-07-30 2003-07-28 施用罗替戈汀的改良透皮递药系统 Pending CN1671375A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02016860A EP1386605A1 (en) 2002-07-30 2002-07-30 Improved transdermal delivery system for the administration of rotigotine
EP02016860.5 2002-07-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2010102984651A Division CN101953819A (zh) 2002-07-30 2003-07-28 施用罗替戈汀的改良透皮递药系统

Publications (1)

Publication Number Publication Date
CN1671375A true CN1671375A (zh) 2005-09-21

Family

ID=30011090

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA038184257A Pending CN1671375A (zh) 2002-07-30 2003-07-28 施用罗替戈汀的改良透皮递药系统
CN2010102984651A Pending CN101953819A (zh) 2002-07-30 2003-07-28 施用罗替戈汀的改良透皮递药系统

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2010102984651A Pending CN101953819A (zh) 2002-07-30 2003-07-28 施用罗替戈汀的改良透皮递药系统

Country Status (19)

Country Link
EP (2) EP1386605A1 (cg-RX-API-DMAC7.html)
JP (2) JP4837916B2 (cg-RX-API-DMAC7.html)
KR (1) KR101016838B1 (cg-RX-API-DMAC7.html)
CN (2) CN1671375A (cg-RX-API-DMAC7.html)
AT (1) ATE322263T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003258539B2 (cg-RX-API-DMAC7.html)
BR (1) BR0313091A (cg-RX-API-DMAC7.html)
CA (1) CA2491366A1 (cg-RX-API-DMAC7.html)
DE (1) DE60304477T2 (cg-RX-API-DMAC7.html)
DK (1) DK1524975T3 (cg-RX-API-DMAC7.html)
ES (1) ES2256780T3 (cg-RX-API-DMAC7.html)
IL (1) IL165918A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA05000350A (cg-RX-API-DMAC7.html)
NO (1) NO333297B1 (cg-RX-API-DMAC7.html)
PL (1) PL217079B1 (cg-RX-API-DMAC7.html)
PT (1) PT1524975E (cg-RX-API-DMAC7.html)
SI (1) SI1524975T1 (cg-RX-API-DMAC7.html)
WO (1) WO2004012730A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200500252B (cg-RX-API-DMAC7.html)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104382850A (zh) * 2014-10-17 2015-03-04 烟台大学 一种罗替戈汀微乳及微乳凝胶
CN106456566A (zh) * 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 含罗替戈汀的经皮递送系统
CN106456567A (zh) * 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
US11033723B2 (en) 2013-07-03 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising an electronic component
US11389410B2 (en) 2012-11-22 2022-07-19 Lts Lohmann Therapie-Systeme Ag Multi-day patch for the transdermal administration of rotigotine
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
EP1796610A4 (en) * 2004-09-29 2012-12-05 Schwarz Pharma Inc TRANSDERMAL THERAPEUTIC SYSTEM FOR PARKINSON'S DISEASE
US7353034B2 (en) 2005-04-04 2008-04-01 X One, Inc. Location sharing and tracking using mobile phones or other wireless devices
CA2739380C (en) * 2008-10-06 2014-12-09 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
WO2011076879A1 (en) * 2009-12-22 2011-06-30 Ucb Pharma Gmbh Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
JP5820469B2 (ja) 2010-04-30 2015-11-24 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダンの経皮組成物
EP2688561B1 (en) 2011-03-24 2018-08-22 Teikoku Pharma USA, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
EP2776020B1 (en) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Methods for the treatment of skin neoplasms
DE102011119043A1 (de) 2011-11-22 2013-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TDS) mit Rotigotin
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
KR101558042B1 (ko) * 2012-07-05 2015-10-07 에스케이케미칼주식회사 로티고틴을 함유한 경피흡수제제
JP6050896B2 (ja) 2012-11-02 2016-12-21 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダン経皮組成物
JP2016135744A (ja) * 2013-05-08 2016-07-28 株式会社 ケイ・エム トランスダーム 貼付剤
WO2014198423A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Dreischichtiges transdermales therapiesystem (tts)
WO2014198422A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Transdermales therapiesystem (tts) mit rotigotin
KR102364378B1 (ko) 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
WO2019234662A1 (en) * 2018-06-07 2019-12-12 Nal Pharmaceutical Group Limited Transdermal drug delivery system containing rotigotine
DK3854388T3 (da) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermalt terapeutisk system omfattende rotigotin og mindst et ikke-aminresistent silikoneklæbestof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
PT1256340E (pt) * 2001-05-08 2003-12-31 Sanol Arznei Schwarz Gmbh Sistema terapeutico transdermico aperfeicoado para o tratamento da doenca de parkinson
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11389410B2 (en) 2012-11-22 2022-07-19 Lts Lohmann Therapie-Systeme Ag Multi-day patch for the transdermal administration of rotigotine
US11033723B2 (en) 2013-07-03 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system comprising an electronic component
CN106456566A (zh) * 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 含罗替戈汀的经皮递送系统
CN106456567A (zh) * 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
CN106456566B (zh) * 2014-05-20 2020-06-16 Lts勒曼治疗系统股份公司 含罗替戈汀的经皮递送系统
US11426359B2 (en) 2014-05-20 2022-08-30 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
US11633367B2 (en) 2014-05-20 2023-04-25 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
US12070521B2 (en) 2014-05-20 2024-08-27 Lts Lohmann Therapie-Systeme Ag Method for adjusting the release of active agent in a transdermal delivery system
US12427119B2 (en) 2014-05-20 2025-09-30 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
CN104382850A (zh) * 2014-10-17 2015-03-04 烟台大学 一种罗替戈汀微乳及微乳凝胶

Also Published As

Publication number Publication date
EP1524975A1 (en) 2005-04-27
NO333297B1 (no) 2013-04-29
SI1524975T1 (sl) 2006-06-30
PL217079B1 (pl) 2014-06-30
AU2003258539B2 (en) 2008-08-21
EP1386605A1 (en) 2004-02-04
CN101953819A (zh) 2011-01-26
KR101016838B1 (ko) 2011-02-22
DE60304477D1 (de) 2006-05-18
EP1524975B9 (en) 2012-02-22
ZA200500252B (en) 2006-01-25
PL374814A1 (en) 2005-10-31
PT1524975E (pt) 2006-07-31
BR0313091A (pt) 2005-06-21
JP2005535687A (ja) 2005-11-24
KR20050056942A (ko) 2005-06-16
CA2491366A1 (en) 2004-02-12
NO20050472L (no) 2005-01-27
ATE322263T1 (de) 2006-04-15
DE60304477T2 (de) 2006-12-14
MXPA05000350A (es) 2005-03-31
ES2256780T3 (es) 2006-07-16
IL165918A0 (en) 2006-01-15
JP5564469B2 (ja) 2014-07-30
JP4837916B2 (ja) 2011-12-14
EP1524975B1 (en) 2006-04-05
DK1524975T3 (da) 2006-07-31
JP2011219485A (ja) 2011-11-04
WO2004012730A1 (en) 2004-02-12
AU2003258539A1 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
JP5564469B2 (ja) ロチゴチン投与のための改善された経皮送達系
US8617591B2 (en) Transdermal delivery system for the administration of rotigotine
US8246980B2 (en) Transdermal delivery system
TR201810322T4 (tr) Rotigotinin kristalin olmayan formunun bir katı dispersiyonunun stabilize edilmesine yönelik polivinilpirolidon.
CN1671365A (zh) 改良透皮递药系统
HK1083459A (en) Improved transdermal delivery system for the administration of rotigotine
HK1083458B (en) Improved transdermal delivery system
HK1062650A (en) Improved transdermal delivery system for the administration of rotigotine
HK1062649A (en) Improved transdermal delivery system
HK1227755A1 (en) Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
HK1227755A (en) Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1083459

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20050921

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1083459

Country of ref document: HK